Jul. 10 at 5:35 PM
$PFE more positives building the future -
Pfizer and Astellas Win FDA Approval For PADCEV Plus Keytruda as First Platinum-Free Perioperative Treatment for Muscle-Invasive Bladder Cancer
11:27 AM EDT, July 10, 2026 (Benzinga Newswire)
First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care
Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus standard of care in cisplatin-eligible patients
